Introduction: Levocetirizine (LCZ) is a new generation antihistamine drug used for the allergic symptoms resulting from various diseases. The present research work focuses on the development of a simple and precise HPLC method for the effective separation and quantitative determination of LCZ and its impurities. Objectives: Eight potential related impurities of LCZ were separated and identified in the bulk drug as well as oral solution dosage form. Results: The separation was achieved on a core shell stationary phase Kinetex bipheyl (250, 4.6×5 μm) column with mobile phase of sodium perchlorate in water and acetonitrile in a gradient elution. The results were monitored and analytes were quantified at 230 nm. Conclusion: The proposed method was stability indicating and was validated as per ICH guidelines for specificity, linearity, precision, accuracy and robustness. The proposed method finds its application in the routine analysis of LCZ in bulk drug and various dosage forms.
INTRODUCTION
Levocetirizine (LCZ) is a third generation piperizine derivative indicated to be used as an effective antihistaminic (H1 blocker). 1 LCZ is the active enantiomer of cetirizine. It is commonly prescribed to relieve from allergic symptoms like watery eyes, running nose, sneezing, hives, and itching. LCZ is commonly taken as an oral pill. [2] [3] [4] [5] [6] The purity of the pharmaceuticals is of utmost concern and the presence of various impurities in the bulk drug and finished pharmaceuticals greatly affect the compliance of the product. 7 Thus it becomes important to provide good and efficient analytical methods which would be able to determine the analyte of interest in a simple, precise and accurate manner. The use of core shell technology stationary phases in the arena of separation science is certainly gaining more importance due to its good chromatographic properties like good peak shape and retention properties. [8] [9] [10] The lifetime of these columns are better when compared to that of conventionally used reverse phase columns. Thus developing analytical methods which involve using the core shell columns provides definitive advantages over traditionally used columns in terms of reproducibility and repeatability of the study. [11] [12] [13] The literature showed various analytical methods reported for the determination of Levocetirizine using HPLC in bulk and dosage forms, in plasma and other biological matrices. Almost all the reported methods indicated the usage of conventional stationary phases. [14] [15] [16] [17] [18] [19] This motivated the authors to develop simple, precise, accurate and robust HPLC method using the core shell technology stationary phase for the determination of LCZ in bulk and formulations.
EXPERIMENTAL

Materials
LCZ was obtained as a gratis sample from Hetero Labs Pvt. Ltd., Hyderabad. HPLC grade acetonitrile and ammonium acetate were purchased from Merck (Darmstadt, Germany). AR grade glacial acetic acid was procured from SD Fine-Chem. Ltd. (Mumbai, India). High purity water was obtained from Millipore Milli -Q plus system (Milford, MA, USA). Water and acetonitrile (50:50 v/v) was used as the diluent and all the final solutions were made in the diluent.
Instrumentation
The liquid chromatographic analysis was performed on an Waters 2695 series HPLC (Waters Corporation) equipped with quaternary solvent manager, a degasser, an ultraviolet detector, an auto sampler and a column compartment with temperature regulation facility. The data acquisition was carried out using the Empower software (version 3)
Chromatographic conditions
The chromatographic separations were carried out on Kinetex bipheyl (250mm x 4.6 mm x 5µm). The mobile phase composed of buffer solution (6.0 gm of sodium perchlorate monohydrate in 1000 mL water along with 2 mL of perchloric acid) of pH 2.0 and acetonitrile in gradient elution. The gradient program set to achieve the separation was 0 /20, 70/25, 80/30, 90/30, 100/40, 110/40, 115/70, 125/70, 130/20, 140/20. The flow rate was 1.5 mL min -1 and the detection was achieved at 230 nm. The injection volume was 50 µL with column oven maintained at 45ºC.
Preparation of LCZ standard solution
The drug substance LCZ was accurately weighed (40 mg) and transferred into a 100 mL flask. About 60 mL of diluent was added and sonicated to dissolve the drug, then made up to the volume with diluent. 5 mL of the above solution was diluted to 100 mL with diluent to result the secondary stock solution. From the secondary stock solution a working standard solution was prepared (1:40 v/v) with the diluent. The stock solution and also the working standards were stored at 10°C and were found to be stable for several days.
Preparation of Sample
The oral solution of LCZ equivalent to 10 mg of LCZ was weighed into 100 mL flask; 40mL diluent was added to dissolve the contents and final volume made up with the diluent to 100 mL. The solution was sonicated for 30 min with intermediate shaking and then the was filtered through 0.45µm membrane filter.
Method Validation
The developed analytical method was validated according to the ICH Q2 (R1) guidelines. 20 The various parameters which were evaluated under the validation process
Precision
The precision of an analytical procedure indicates the closeness of agreement between a set of measurements obtained from multiple sampling of the same sample under the prescribed conditions. For system precision and method precision standard solution and sample solutions (unspiked and spiked) were prepared as per test method and injected into the chromatographic system respectively.
Accuracy
It shows the closeness of the true value which is accepted or standard and the value which is obtained after the experimentation. In accuracy study, LCZ and its impurities were spiked to the placebo and sample solutions respectively at a concentration ranging from LOQ to 150%. All the samples were injected in triplicate at each level.
Linearity and range
The linearity of an analytical method is the ability of the method to respond in direct proportion to that of concentration. The specific concentration levels within which the method shows a direct relation between the response and concentration is known as the linearity. The linearity was established from LOQ to 150% of the specification level of LCZ and the impurities.
Robustness
It shows the ruggedness of the method when deliberate but small changes are made to the parameters of the analytical method. This parameter builds in confidence into the method indicating the extent to which the method is capable of sustaining small variations while transfer of the method. To demonstrate the robustness of the proposed method in the present study, deliberate changes in the flow rate and column temperature were made. The observations were made by evaluating the system suitability parameters of the standard and % RSD for the sample solutions.
Limit of detection (LOD) and limit of quantification (LOQ)
The determination of limit of detection and quantification of the drug and its impurities indicate the sensitivity of the method. It provides an estimate about the minimum levels from where the analytes can be invariably determined using the analytical method. LOD is the concentration where the signal to noise ratio is 3:1 and for LOQ it is 10:1.
RESULTS AND DISCUSSION
Optimization of HPLC conditions
The development of a HPLC method for the determination of LCZ and its related substances was aimed at proposing a stability indicating method that can quantify LCZ in the presence of its excipients with good precision and accuracy ( Figure 1 ). The first step was to find an appropriate wavelength where LCZ and all its impurities can be effectively determined without any compromise (which is commonly observed for compounds with different absorption maximum). A suitable wavelength was found experimentally after measuring spectra of the components to be separated and subsequently testing the detector response of analytes at 230 nm. LCZ and its related substances showed different affinities and thereby various retentions for chromatographic stationary phases attributed to their differences in molecular structures (Figure 2 ). The selection of suitable column for the separation of LCZ and its 9 impurities was critical. The approach was based on column screening studies where a number of columns with different chemistries were tried. Finally, Kinetex biphenyl column produced the best separation with optimum resolution among the various critical pairs. The organic component of the method was chosen with respect to obtain good resolution and low back pressure. The column temperature was maintained at 45ºC. The retention of the analytes on the stationary phase is dependent on the pH of the aqueous component. This determines the analytes to be either in ionized or neutral form thereby exerting an effect on their retention behaviour owing to interactions based the polarities of stationary phase and the molecules. The aim of the present study is to develop a reversedphase high-performance liquid chromatography procedure for the determination of LCZ in the oral solution dosage forms. LCZ is relatively non-polar compound as indicated by partition coefficient (log p = 4.94 and 6.03) [15] , and is well retained on traditional C18 bonded phases. The initial trials were carried out with aqueous buffer solutions of pH 3.0, 4.0, 5.0, 5.5 and 6.0 with organic phase being methanol or acetonitrile. The method was optimized in keeping view of adequate separation of the degradation products from the main peak. The developed chromatographic method was capable of determining LCZ in its oral solution dosage forms.
Method validation
The developed method was validated to establish the specificity, precision, linearity, accuracy and robustness according to ICH guidelines. 16 In the present study where the separation of 9 impurities was carried only two impurities (Imp 1 and N-Oxide impurity) were quantified. Since the other related impurities are process related they need not be quantified and were included to confirm their relative retention time (Shown in Table 1 ).
Specificity
The specificity of the method was performed by ensuring the separation of the drug from all the interferences Figure 2 . The specificity of the method was established by evaluating the peak purity of LCZ and all its impurities. The results showed LCZ to be pure and all the degradation products were separated and no other peaks were interfering with it ( Table 1) .
Limit of detection (LOD) and limit of quantification (LOQ)
The LOD and LOQ of the developed method were determined by injecting sample solutions of LCZ and all its impurities individually by progressively decreasing the concentration of the analyte (Table 3) .
Linearity
The linearity of the method was checked by injecting six concentration levels of LCZ, Imp 1 and N-Oxide impurity ranging from LOQ to 150% of specification level. Each solution was injected in triplicate and the mean was taken for calculation. Calibration equation was obtained from linear regression analysis and the correlation coefficient was found to be 0.99961which shows that the method is linear. The regression equation for the calibration curve was found to be y = 32224.51x + 46741 (Table 2) .
Accuracy
The accuracy of the method was evaluated in triplicate at three concentration levels, i.e. 50%, 100% and 150% levels by spiking the drug LCZ and all the impurities in tablet placebo. The percentage of recovery of the drug was calculated at each level. The percentage recovery of the LCZ and its impurities ranged from 98.9% to 100.7% indicating the accuracy of the method (Table 5) .
Precision
The precision studies are performed to evaluate the repeatability of the method. The repeatability of the proposed method was demonstrated by analyzing six separate samples solutions of LCZ spiked with its 8 impurities (0.1 % level with respect to LCZ concentration). The %RSD for the peak areas of different injections were calculated and were found to be less than 2 showing the method to be highly precise. The results are shown in Table 4 .
Robustness
The experimental conditions were deliberately changed in order to determine the robustness of the developed method and percentage assay and tailing factor of the main peak was evaluated. Observation of the results for deliberately changed chromatographic conditions (flow rate, and column temperature) revealed percentage assay and also the tailing factor were within the limits, illustrating the robustness of the method.
CONCLUSION
A simple, precise and accurate HPLC method was developed to separate and quantify LCZ and its related impurities. The developed method was validated according to ICH guidelines and demonstrated to be specific, linear, precise, accurate and robust. The specificity results indicated the stability indicating power of the proposed chromatographic method. The method can be successfully employed in regular analysis and quality control laboratories.
